Tiza Wuri Mawaddah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tiza Wuri Mawaddah has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Chairul Anwar Nidom
Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia; Professor Nidom Foundation, Surabaya, Indonesia; Global Biosains Teknologi, Malang, Indonesia; Riset AIRC Indonesia, Surabaya, Indonesia
3 shared publications - Reviany Vibrianita Nidom
Professor Nidom Foundation, Surabaya 60236, Indonesia
3 shared publications - Astria Novitasari Nidom
Doctoral Program of Medical Science, Faculty of Medicine Universitas Airlangga Surabaya Indonesia
2 shared publications - Elisa Diah Pratiwi
Faculty of Veterinary Medicine Universitas Airlangga Surabaya Indonesia
2 shared publications - Irma Yurita Rosytania
Department of Research and Development Laboratory Professor Nidom Foundation Surabaya Indonesia
2 shared publications - Jonny Jonny
Faculty of Military Medicine, Indonesia Defense University, Bogor 16810, Indonesia
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Narra Sains Indonesia in Narra J
- Vol. 6 (3) , e3140
Enhancing immunogenicity: Evaluating the polio antigen immune response in hexavalent vaccine formulations
Hexavalent vaccines simplify childhood immunization by combining antigens against six diseases in a single formulation; however, the immunogenicity of each component must be evaluated. This study assessed poliovirus-specific immunoglobulin G (IgG) responses elicited by candidate hexavalent vaccines containing different doses of Sabin strain-derived inactivated poliovirus vaccine (sIPV). A preclinical study was conducted using 40 Wistar rats allocated to five groups: hexavalent vaccine containing low-, medium-, or high-dose sIPV; pentavalent vaccine combined with sIPV; or adjuvant control. Each group comprised four male and four female rats. The animals received primary immunization at week 0 and booster doses at weeks 4 and 8. Serotype-specific IgG titers were measured at weeks 0, 4, 8, and 12 using indirect enzyme-linked immunosorbent assay. Antibody responses were analyzed using repeated-measures analysis of variance. Titers against poliovirus serotypes 1, 2, and 3 were negligible at baseline and remained low at week 4. Marked responses were observed in all vaccinated groups at week 8, followed by lower titers at week 12. Significant between-group differences were detected at weeks 8 and 12 for serotype 1 (p<0.001 and p=0.010), serotype 2 (both p<0.001), and serotype 3 (both p=0.010). However, no consistent dose–response pattern was observed across serotypes, time points, or sexes. All animals survived and gained body weight during follow-up. The candidate hexavalent formulations elicited marked poliovirus-specific binding-IgG responses, supporting further preclinical evaluation using validated serological and serotype-specific neutralization assays.
- 3 September 2026
- Published by Narra Sains Indonesia in Narra J
- Vol. 6 (3) , e3140
Open AccessEnhancing immunogenicity: Evaluating the polio antigen immune response in hexavalent vaccine formulations
Hexavalent vaccines simplify childhood immunization by combining antigens against six diseases in a single formulation; however, the immunogenicity of each component must be evaluated. This study assessed poliovirus-specific immunoglobulin G (IgG) responses elicited by candidate hexavalent vaccines containing different doses of Sabin strain-derived inactivated poliovirus vaccine (sIPV). A preclinical study was conducted using 40 Wistar rats allocated to five groups: hexavalent vaccine containing low-, medium-, or high-dose sIPV; pentavalent vaccine combined with sIPV; or adjuvant control. Each group comprised four male and four female rats. The animals received primary immunization at week 0 and booster doses at weeks 4 and 8. Serotype-specific IgG titers were measured at weeks 0, 4, 8, and 12 using indirect enzyme-linked immunosorbent assay. Antibody responses were analyzed using repeated-measures analysis of variance. Titers against poliovirus serotypes 1, 2, and 3 were negligible at baseline and remained low at week 4. Marked responses were observed in all vaccinated groups at week 8, followed by lower titers at week 12. Significant between-group differences were detected at weeks 8 and 12 for serotype 1 (p<0.001 and p=0.010), serotype 2 (both p<0.001), and serotype 3 (both p=0.010). However, no consistent dose–response pattern was observed across serotypes, time points, or sexes. All animals survived and gained body weight during follow-up. The candidate hexavalent formulations elicited marked poliovirus-specific binding-IgG responses, supporting further preclinical evaluation using validated serological and serotype-specific neutralization assays.
- Open Access
- 15 March 2026
- Published by Wiley in Animal Models and Experimental Medicine
Phenotypic profiling of pristane‐induced mimicking human systemic lupus erythematosus in Macaca fascicularis
Background: The development of nonhuman primate models that replicate human systemic lupus erythematosus (SLE) remains limited. This study aimed to develop a pristane‐induced SLE model in Macaca fascicularis and evaluate its capacity to mimic human‐like clinical and laboratory immunological alterations. Methods: An experimental, single‐arm investigation was performed using six female M. fascicularis (2–3 years old, 3–4 kg), which received a single intraperitoneal pristane injection (5 mL/kg body weight) to induce SLE and were monitored biweekly. Results: Throughout the 24‐week study period, all macaques developed hallmark SLE‐like changes without requiring a booster, including a pronounced increase in antinuclear antibody titers ( p = 0.002), with anti‐dsDNA positivity detected at the study endpoint. Significant decline was observed in hemoglobin, leukocyte, and lymphocyte count ( p < 0.05), reflecting hematologic perturbations consistent with human SLE. Physiologic deterioration, manifested as hyperthermia and weight loss, also emerged early ( p = 0.001). Biochemical assessment demonstrated mild hepatic and renal dysfunction marked by elevated serum glutamic pyruvic transaminase (SGPT) and urea concentrations ( p < 0.05). Uniform proteinuria further indicated renal involvement, although the absence of hematuria suggests a spectrum of renal injury that may be less severe than that observed in advanced human SLE and may require longer observation. Conclusion: Overall, the reproducibility of autoantibody elevation and multisystem involvement demonstrates the model's translational potential. This nonhuman primate model offers a significant framework for investigating SLE pathogenesis and assessing novel therapy approaches.
- 15 March 2026
- Published by Wiley in Animal Models and Experimental Medicine
Open AccessPhenotypic profiling of pristane‐induced mimicking human systemic lupus erythematosus in Macaca fascicularis
Background: The development of nonhuman primate models that replicate human systemic lupus erythematosus (SLE) remains limited. This study aimed to develop a pristane‐induced SLE model in Macaca fascicularis and evaluate its capacity to mimic human‐like clinical and laboratory immunological alterations. Methods: An experimental, single‐arm investigation was performed using six female M. fascicularis (2–3 years old, 3–4 kg), which received a single intraperitoneal pristane injection (5 mL/kg body weight) to induce SLE and were monitored biweekly. Results: Throughout the 24‐week study period, all macaques developed hallmark SLE‐like changes without requiring a booster, including a pronounced increase in antinuclear antibody titers ( p = 0.002), with anti‐dsDNA positivity detected at the study endpoint. Significant decline was observed in hemoglobin, leukocyte, and lymphocyte count ( p < 0.05), reflecting hematologic perturbations consistent with human SLE. Physiologic deterioration, manifested as hyperthermia and weight loss, also emerged early ( p = 0.001). Biochemical assessment demonstrated mild hepatic and renal dysfunction marked by elevated serum glutamic pyruvic transaminase (SGPT) and urea concentrations ( p < 0.05). Uniform proteinuria further indicated renal involvement, although the absence of hematuria suggests a spectrum of renal injury that may be less severe than that observed in advanced human SLE and may require longer observation. Conclusion: Overall, the reproducibility of autoantibody elevation and multisystem involvement demonstrates the model's translational potential. This nonhuman primate model offers a significant framework for investigating SLE pathogenesis and assessing novel therapy approaches.
- Open Access
- 9 February 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 144-154
ANA Serum in a Non-Human Primate (Macaca fascicularis) Model of Systemic Lupus Erythematosus Induced by Pristane
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the production of antinuclear antibodies (ANA). While murine models are widely used for lupus research, their translational value is limited by physiological differences. Macaca fascicularis, a non-human primate, offers a closer model due to its genetic and immunological similarities to humans. Pristane (2,6,10,14-tetramethylpentadecane), a hydrocarbon oil, can induce lupus-like manifestations, including ANA production, but evidence in Macaca fascicularis remains scarce. This study assessed ANA titers following pristane induction in seven macaques, with one serving as a negative control. A single intraperitoneal dose of pristane (5 mL/kg) was administered, and ANA titers were evaluated biweekly using ELISA. ANA seropositivity (titer ≥1:80) was first detected at week 4, increasing to four macaques by week 8 and persisting at four positives in week 10. The duration of ANA positivity varied across individuals, ranging from a single week to continuous six-week responses, with one showing a biphasic pattern. The control macaque remained negative throughout. Clinical observations included alopecia, weight loss, lymphopenia, hematuria, and proteinuria in ANA-positive animals. In conclusion, pristane induced measurable autoimmunity in Macaca fascicularis, supporting its utility as a translational model for lupus research and preclinical testing of therapeutic interventions.
- 9 February 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 144-154
Open AccessANA Serum in a Non-Human Primate (Macaca fascicularis) Model of Systemic Lupus Erythematosus Induced by Pristane
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the production of antinuclear antibodies (ANA). While murine models are widely used for lupus research, their translational value is limited by physiological differences. Macaca fascicularis, a non-human primate, offers a closer model due to its genetic and immunological similarities to humans. Pristane (2,6,10,14-tetramethylpentadecane), a hydrocarbon oil, can induce lupus-like manifestations, including ANA production, but evidence in Macaca fascicularis remains scarce. This study assessed ANA titers following pristane induction in seven macaques, with one serving as a negative control. A single intraperitoneal dose of pristane (5 mL/kg) was administered, and ANA titers were evaluated biweekly using ELISA. ANA seropositivity (titer ≥1:80) was first detected at week 4, increasing to four macaques by week 8 and persisting at four positives in week 10. The duration of ANA positivity varied across individuals, ranging from a single week to continuous six-week responses, with one showing a biphasic pattern. The control macaque remained negative throughout. Clinical observations included alopecia, weight loss, lymphopenia, hematuria, and proteinuria in ANA-positive animals. In conclusion, pristane induced measurable autoimmunity in Macaca fascicularis, supporting its utility as a translational model for lupus research and preclinical testing of therapeutic interventions.